OTCMKTS:PMCBD PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free PMCBD Stock Alerts $2.11 -0.01 (-0.47%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.08▼$2.1250-Day Range$1.95▼$2.5252-Week Range$5.56▼$55.50Volume5,644 shsAverage Volume8,831 shsMarket Capitalization$3.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get PharmaCyte Biotech alerts: Email Address Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About PharmaCyte Biotech Stock (OTCMKTS:PMCBD)PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.Read More PMCBD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMCBD Stock News HeadlinesMarch 19, 2024 | investorplace.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024February 22, 2024 | investing.comPharmaCyte Biotech Inc (PMCB)April 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” October 27, 2023 | ft.comExploring beauty’s biotech frontierMay 26, 2023 | seekingalpha.comPMCB PharmaCyte Biotech, Inc.May 11, 2023 | marketwatch.comPharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender OfferApril 28, 2023 | bizjournals.comBaltimore Biotech NewsMarch 30, 2023 | techcrunch.comBiotech & HealthApril 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” October 7, 2022 | finance.yahoo.comPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueSeptember 28, 2022 | finanznachrichten.deBLACK BIRD BIOTECH INCJuly 28, 2022 | finance.yahoo.comPharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationJuly 19, 2022 | apnews.comPharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model StudyJuly 5, 2022 | finance.yahoo.comIROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORSJune 2, 2022 | seekingalpha.comPharmaCyte Biotech announces $10M share buyback programJune 2, 2022 | seekingalpha.comPharmaCyte Biotech stock rises on $10M stock buyback planJune 2, 2022 | apnews.comPharmaCyte Biotech to Implement $10-Million Share Repurchase ProgramMay 23, 2022 | stockhouse.comPharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant AscitesFebruary 10, 2022 | finance.yahoo.comPharmaCyte Biotech, Inc. (PMCB)January 6, 2022 | finance.yahoo.comPharmaCyte Biotech to Present at H.C. Wainwright BioConnect ConferenceDecember 28, 2021 | businesswire.comPharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability StudyDecember 8, 2021 | stockhouse.comPharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing AssayNovember 30, 2021 | businesswire.comPharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical StudyNovember 12, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin IrritationSeptember 16, 2021 | feeds.benzinga.comWhy Are PharmaCyte Shares Moving Higher On Thursday?August 12, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Closing of $15-Million Public OfferingSee More Headlines Receive PMCBD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:PMCBD CUSIPN/A CIKN/A Webwww.pharmacyte.com Phone(917) 595-2850FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.09% Return on Assets-43.39% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,671,000Free FloatN/AMarket Cap$3.53 million OptionableNot Optionable Beta0.27 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesKenneth L. WaggonerChairman, President, CEO & SecretaryCarlos A. TrujilloChief Financial Officer & DirectorWalter H. GünzburgsChief Scientific OfficerLinda S. SherChief Medical OfficerJosé L. IglesiasChief Medical OfficerKey CompetitorsFinch Therapeutics GroupNASDAQ:FNCHKiromic BioPharmaNASDAQ:KRBPLadRxOTCMKTS:CYTRTRACON PharmaceuticalsNASDAQ:TCONAvalon GloboCareNASDAQ:ALBTView All Competitors PMCBD Stock Analysis - Frequently Asked Questions How have PMCBD shares performed in 2024? PharmaCyte Biotech's stock was trading at $2.16 on January 1st, 2024. Since then, PMCBD shares have decreased by 2.3% and is now trading at $2.11. View the best growth stocks for 2024 here. How do I buy shares of PharmaCyte Biotech? Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PMCBD) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
